Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $110.
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $110.